Develops laser-based medical systems for the treatment of eye diseases, focusing on innovative therapies for ophthalmic conditions.
IRIDEX Corporation is a leading provider of advanced ophthalmic medical technologies, specializing in therapeutic laser systems, delivery devices, and consumable instrumentation designed to combat sight-threatening eye diseases. The company's comprehensive product portfolio includes state-of-the-art laser consoles like the Cyclo G6 system, tailored for treating glaucoma, and the IQ 532 and IQ 577 systems, utilized in laser photocoagulation for diabetic macular edema and various retinal conditions. Additionally, IRIDEX offers the OcuLight series of laser photocoagulation systems, essential for addressing proliferative diabetic retinopathy, macular holes, and retinal tears.
Innovative delivery devices are also integral to IRIDEX's offerings, such as the TxCell scanning laser delivery system, enabling physicians to perform precise multi-spot pattern scanning. The company's product line further includes accessories like the slit lamp adapter for enhanced diagnostic and treatment capabilities using standard slit lamps, and the laser indirect ophthalmoscope crucial for treating peripheral retinal disorders. IRIDEX is known for its MicroPulse P3 Probe, facilitating MicroPulse transscleral laser therapy with the Cyclo G6 system, alongside specialized probes like the G-Probe series for addressing glaucoma and vitrectomy procedures.
Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves a diverse clientele including ophthalmologists, hospitals, surgical centers, and veterinary practices worldwide. The company markets its cutting-edge products through direct sales channels in the United States and international distribution partners. With a legacy of innovation in ophthalmic medical technology, IRIDEX continues to advance the treatment landscape for eye diseases, ensuring patients receive state-of-the-art therapeutic solutions to preserve and improve vision.